Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 4, 2009, Pages 165-176

  Zhu, Yuao ^a   Curtis, Maria ^a   Qi, Xiaoping ^a   Miller, Michael D ^a   Borroto Esoda, Katyna ^a  

^a GILEAD SCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; GUANINE; NUCLEOSIDE; NUCLEOTIDE; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINONE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG POTENTIATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; CELL LINE; CELL SURVIVAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HEPATITIS B;

ADENINE; ANTIVIRAL AGENTS; CELL LINE; CELL SURVIVAL; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; NUCLEOSIDES; NUCLEOTIDES; PHOSPHONIC ACIDS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 65549083011     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020901900404     Document Type: Article

References (55)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11:97-107. (Pubitemid 38365759)
2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:1733-1745.
3. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312-323. (Pubitemid 23319890)
4. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695. (Pubitemid 41007823)
5. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217. (Pubitemid 39296307)
6. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008; 48 Suppl 1:S2-S19.
7. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64:51-68.
8. Lai C-L, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36:687-696. (Pubitemid 36337972)
9. Gish RG, Trinh H, Leung NW, et al. Safety and antiviral activity of emtricitabine (FTC) for the treatment of chronic hepatitis B infection. A two year study. J Hepatol 2005; 43:60-66. (Pubitemid 40805273)
10. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588. (Pubitemid 350294224)
11. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE, IV. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005; 10:625-633. (Pubitemid 41224954)
12. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
13. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44:1656-1665. (Pubitemid 44953670)
14. Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126:81-90. (Pubitemid 38040726)
15. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126:91-101. (Pubitemid 38040727)
16. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125:292-297. (Pubitemid 36929407)
17. Locarnini S, Qi X, Arterburn S, et al. Incidence and predictors of emergence of HBV mutations associated with ADV resistance during 4 years of ADV therapy for patients with chronic hepatitis B. 40th Annual Meeting of the European Association for the Study of the Liver. 13-17 April 2005, Paris, France. Abstract 36.
18. Heathcote EJ, Gane E, DeMan R, et al. Randomized, double-blind comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-positive chronic hepatitis B (CHB): Study GS-US-174-0103. Hepatology 2007; 46:861A.
19. Marcellin P, Buti M, Kraslev Z, et al. Randomized, double-blind comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. Hepatology 2007; 46:290A-291A.
20. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. (Updated 3 November 2008. Accessed 20 February 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
21. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, De Clercq E, Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother 1994; 38:2180-2182. (Pubitemid 24278823)
22. Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat 2000; 7:161-165. (Pubitemid 30177107)
23. Delaney WE, IV, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471-2477. (Pubitemid 43993188)
24. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006; 131:1253-1261. (Pubitemid 44515103)
25. Lacombe K, Ollivet A, Gozlan J, et al. A novel hepatitis B virus mutation with resistance to adefovir but not to tenofovir in an HIV-hepatitis B virus-co-infected patient. AIDS 2006; 20:2229-2231. (Pubitemid 44684715)
26. Brunelle MN, Lucifora J, Neyts J, et al. In vitro Activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother 2007; 51:2240-2243. (Pubitemid 46903127)
27. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46:531-538. (Pubitemid 46201724)
28. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734. (Pubitemid 41376852)
29. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
30. Lampertico P, Vigano M, Manenti E, Lavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42:1414-1419. (Pubitemid 43260045)
31. Lampertico P, Vigano M, Manenti E, Lavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133:1445-1451. (Pubitemid 350047463)
32. Ladner SK, Otto MJ, Barker CS, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997; 41:1715-1720.
33. Qi X, Xiong S, Yang H, Miller M, Delaney WE, IV. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12:355-362. (Pubitemid 46787980)
34. Prichard MN, Shipman C, Jr. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1996; 1:9-20.
35. Elion GB, Singer S, Hitchings GH. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. J Biol Chem 1954; 208:477-488.
36. Borroto-Esdoa K, Vela JE, Myrick F, Ray AS, Miller MD. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther 2006; 11:377-384. (Pubitemid 43823557)
37. Selleseth DW, Talarico CL, Miller T, Lutz MW, Biron KK, Harvey RJ. Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Antimicrob Agents Chemother 2003; 47:1468-1471. (Pubitemid 36368623)
38. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997; 71:9392-9399. (Pubitemid 27492382)
39. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75:311-322.
40. Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analogue therapy. Proc Natl Acad Sci U S A 2004; 101:638-640. (Pubitemid 38084689)
41. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431. (Pubitemid 43069226)
42. Korba BE. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res 1996; 29:49-51. (Pubitemid 26094518)
43. Korba BE, Cote P, Hornbuckle W, Schinazi R, Gerin JL, Tennant BC. Enhanced antiviral benefit of combination therapy with lamivudine and famciclovir against WHV replication in chronic WHV carrier woodchucks. Antiviral Res 2000; 45:19-32. (Pubitemid 30074190)
44. Colledge D, Civitico G, Locarnini S, Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob Agents Chaemother 2000; 44:551-560. (Pubitemid 30117940)
45. Seigneres B, Martin P, Werle B, et al. Effects of pyrimidine and purine analogue combinations in the duck hepatitis B virus infection model. Antimicrob Agents Chaemother 2003; 47:1842-1852. (Pubitemid 36637804)
46. Delaney WE, IV, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chaemother 2004; 48:3702-3710. (Pubitemid 39310516)
47. Sung JJY, Lai JY, Zeuzem S, et al. A randomized double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis. J Hepatol 2003; 38:25-26. Abstract 69.
48. Lau GK, Cooksley H, Ribeiro RM, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007; 12:705-718. (Pubitemid 47235485)
49. Prichard MN, Prichard LE, Shipman C, Jr. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chaemother 1993; 37:540-545.
50. Berenbaum MC. What is synergy? Pharmacol Rev 1989; 41:93-141.
51. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48:391-398.
52. Benhamou Y, Fleury H, Trimoulet P, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. Hepatology 2006; 43:548-555.
53. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. Hepatology 2006; 44:1110-1116. (Pubitemid 44748362)
54. Schmutz G, Nelson M, Lutz T, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20:1951-1954. (Pubitemid 44427612)
55. Bani-Sadr F, Palmer P, Scieux C, Molina JM. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus. Clin Infect Dis 2004; 39:1062-1064. (Pubitemid 39313467)